From: A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047
Pathway Name | P-Value | Ratio | Component genes in the pathway |
---|---|---|---|
Interferon Signaling | 0.001 | [4/29] | IRF1, IRF9, TAP1, IFNGR1 |
Ephrin Receptor Signaling | 0.011 | [8/193] | CXCR4, ABI1, RAP1A, MAPK1, WASL, MAP4K4, GNAI3, PAK1 |
Role of BRCA1 in DNA Damage Response | 0.013 | [4/52] | RPA1, RFC3, MSH2, E2F3 |
Nicotinate and Nicotinamide Metabolism | 0.019 | [5/129] | NNMT, ENPP2, MAPK1, ENPP1, PAK1 |
Fcy Receptor -mediatedPhagocytosis in Macrophages andMonocytes | 0.028 | [5/104] | RPS6KB1, LYN, MAPK1, VAMP3, PAK1 |
Riboflavin Metabolism | 0.032 | [2/49] | ENPP2, ENPP1 |
Endoplasmic Reticulum Stress Pathway | 0.041 | [2/18] | XBP1, TAOK3 |
Pantothenateand CoA Biosynthesis | 0.046 | [2/63] | ENPP2, ENPP1 |
CXCR4 Signaling | 0.052 | [6/164] | CXCR4, RHOB, LYN, MAPK1, GNAI3, PAK1 |
PI3K/AKT Signaling | 0.055 | [5/135] | RPS6KB1, SFN, MAPK1, YWHAH, PPP2R5A |
Integrin Signaling | 0.056 | [7/198] | RHOB, RAP1A, MAPK1, TSPAN6, WASL, ARF4, PAK1 |